Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (30449)	4/15/1999 2:12:00 PM
From: M. LaMancha	Respond to of 122087

GZMO -- since we've opened the door to going long, consider GZMO. I went in for 2K shares yesterday at 3 1/2. CSFB initiated buy rating, which ran on Reuters about 25 minutes ago. GZMO is in a white hot angiogenesis sector; has licensed products from Judah Folkman; has access to over $11 million of its own cash; $30 million equity credit line through Genzyme (it is a division of Genzyme); and potential to receive from Schering-Plough, up to $30.0 million in future patent, product development and sales milestone fees, in addition to royalties on product sales. Stock is about a point and a half above its low. Not much downside.